Goddard Glenn
- SEC CIK
- 0001581992
No open-market purchases or sales filed in the past year.
Current role at each company
- NTLA Intellia Therapeutics, Inc.EVP, Chief Financial Officeras of Mar 5, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Goddard Glenn as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 5, 2024 (view filing) | Jan 3 | 2 days | Goddard GlennEVP, Chief Financial Officer | SSale | −5.37K | $29.46 | −$158.1K | −11.7%40.6K after | |
| Jan 6, 2023 (view filing) | Jan 4 | 2 days | Goddard GlennEVP, Chief Financial Officer | SSale | −2.43K | $37.21 | −$90.3K | −13.6%15.4K after | |
| Mar 3, 2022 (view filing) | Jan 1 | 61 days | Goddard GlennEVP, Chief Financial Officer | SSale | −1.01K | $112.24 | −$113.7K | −33.1%2.05K after | From original |
| Sep 9, 2021 (view filing) | Sep 7 | 2 days | Goddard GlennEVP, Chief Financial Officer | SSale | −3.48K | $180.12 | −$627.2K | −100.0%0 after | |
| Sep 1, 2021 (view filing) | Aug 30-31 | 2 days | Goddard GlennEVP, Chief Financial Officer | SSale | −30.0K | $159.45 | −$4.78M | −100.0%0 after | 9 lots |
| Aug 6, 2021 (view filing) | Aug 5 | 1 day | Goddard GlennEVP, Chief Financial Officer | SSale | −20.0K | $151.05 | −$3.02M | −100.0%0 after | 3 lots |